Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. “Ms. Connelly is a seasoned board leader with extensive o.

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Viking Therapeutics

Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.

These 2 Biotech Stocks Are Set to Soar

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne muscular dystrophy and five to siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. “On behalf of Sarepta and the se.

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. on Friday, Sept. 6, 2024, at 9:15 a.m. E.T. The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarep.

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm  Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.

Bull Signal Flashing for Sarepta Therapeutics Stock

Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.

Biotech Stock Flashing Bull Signal

Vertex Pharmaceuticals

Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.

2 Biotech Stocks to Buy Hand Over Fist in August

Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Allogene Therapeutics Inc

Blueprint Medicines

CRISPR Therapeutics

Precision Biosciences

REGENXBIO

Voyager Therapeutics

With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.

7 Biotech Stocks to Buy for Their Game-Changing Potential

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Doug Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President & Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Anupam Rama - JMP Gena Wang - Barclays Brian Abrahams - RBC Capital Salveen Richter - Goldman Sachs Ritu Baral - TD Cowen Mike Ulz - Morgan Stanley Brian Skorney - Baird Uy Ear - Mizuho Robert Finke - Guggenheim David Hoang - Citigroup Kristen Kluska - Cantor Fitzgerald Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore Gil Blum - Needham & Company Operator Good afternoon and thank you for standing by. Welcome to the Sarepta Therapeutics Second Quarter 2024 Financial Results Conference Call.

Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024. “The second quarter of 2024 represents the most significant achievement in the advancement of medicine for Duchenne since researchers identified that lack of dystrophin was the underlying cause of Duchenne in 1986. Based on a wealth of compelling clinical evidence, the FDA broadened access to our ge.

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

Ultragenyx Pharmaceutical

Bio-Techne

When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before.

3 Genomics Stocks That May Transform Personalized Medicine

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Sarepta Therapeutics (SRPT) a New Buy Stock

Artivion

Krystal Biotech

Micron Technology

Seagate Technology Holdings PLC

Tidewater

Vericel

None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

7 Best Stocks For Magnificent Earnings Growth Next Year. See Who's New.

Axsome Therapeutics

Halozyme Therapeutics

Moderna

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

5 Biotech Stocks to Bet On Bright Industry Prospects

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue growth and earnings, with a $130 billion cumulative U.S. revenue opportunity. The recent pullback is an attractive investment opportunity for long-term investors.

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade

Exact Sciences

United Therapeutics

In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

3 Biotech Stocks You Should Know About

Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?

Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.

News for Sarepta Therapeutics Stock (SRPT)